Scott Tykodi, MD, PhD

Financial relationships

  • Attribution: 
    Other
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Merck
    Topic: 
    clinical research
    Date added: 
    03/05/2023
    Relationship end date: 
    10/31/2026
  • Attribution: 
    Other
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    AVEO Oncology
    Topic: 
    clinical research
    Date added: 
    03/05/2023
    Relationship end date: 
    04/30/2026
  • Attribution: 
    Other
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Bristol Myers Squibb
    Topic: 
    clinical research
    Date added: 
    03/05/2023
    Relationship end date: 
    06/30/2025
  • Attribution: 
    Other
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Exelixis
    Topic: 
    clinical research
    Date added: 
    03/05/2023
    Relationship end date: 
    05/31/2024
  • Attribution: 
    Other
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Pfizer
    Topic: 
    clinical research
    Date added: 
    03/05/2023
    Relationship end date: 
    03/31/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Bristol Myers Squibb
    Topic: 
    advisory board
    Date added: 
    03/05/2023
    Relationship end date: 
    10/07/2021
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Targeted Oncology
    Topic: 
    Regional CME virtual presentation
    Date added: 
    03/05/2023
    Relationship end date: 
    02/02/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    FirstWord
    Topic: 
    phone interview
    Date added: 
    03/05/2023
    Relationship end date: 
    07/13/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Exelixis
    Topic: 
    advisory board
    Date added: 
    03/05/2023
    Relationship end date: 
    06/24/2021
Return to 2023 Summit on Cancer Health Disparities: Reframing and Addressing Barriers to Adoption of Precision Oncology